National Institute for Health and Clinical Excellence (NICE)
Children and young people need accurate, accessible information about their healthcare
New draft guidance from NICE published today recommends ensuring children and young people are fully informed about their health so that they are empowered to take an active role in their healthcare
The healthcare system can be intimidating to younger patients, and poor experiences may lead to anxiety around engaging with the system later in life and poorer health outcomes. This draft guidance aims to improve the healthcare experience of babies, children, and young people with the hope that this can improve their health outcomes and wellbeing.
The draft guidance emphasises the need to provide children and young people with clear and accurate information which can be tailored to an individual patient’s level of maturity and understanding. Information materials should be developed in partnership with young people and presented in a range of formats using words and images.
The draft guidance also recommends that young people and their carers should be warned that some medical information available online may be inaccurate. They should be advised where they can access additional sources of information about their care or condition that is accurate, credible, and evidence-based.
Dr Paul Chrisp, director of the Centre for Guidelines at NICE, said: “We know that young people are more likely to look for health advice online or on social media so it’s important they are advised which sources are reliable and trustworthy. Younger patients have historically been seen as more ‘passive’ recipients of healthcare than adults, but supporting them to truly understand their condition and treatment can help them to feel more confident engaging with healthcare staff. We’re very pleased that this draft guideline has been developed with input from children and young people, and hope that it will provide healthcare staff with clear guidance on how to engage effectively with younger patients.”
Catherine White, Chair of the Guideline Committee, said: “By placing babies, children and young people at the heart of their healthcare, we can improve not only their experience of the healthcare system but also their health outcomes. An important way to do this is by finding ways to communicate with children and young people in a way that is engaging and understandable. We hope our draft recommendations will enable excellent healthcare experiences and the committee looks forward to hearing feedback about this draft guideline from the healthcare community, including children, young people and parents and carers.”
The draft recommendations also state that children and young people should be involved in shared decision making over their care, and should fully understand their rights and responsibilities about privacy, confidentiality and when consenting to treatment. Conversations should be a two-way street and appointments may need to be lengthened to provide the time to do this.
The draft guidance recognises the important role parents, carers, and advocates play in ensuring younger patients feel supported during appointments, although patients should be offered the opportunity to speak to a healthcare professional in private where appropriate in line with current practice.
Although the recommendations in this draft were mostly developed before the COVID-19 pandemic, the committee has reviewed the draft in relation to COVID-19 and made changes where necessary.
Dr Chrisp added, “We recognise that some of these recommendations, such as allowing children and young people longer to speak to healthcare professionals, could present challenges for some time to come during the pandemic but is something that we should aim to do.”
The draft guidance is out for public consultation until 16 April 2021 and NICE is keen to hear the views of parents and carers of babies and young children, children and young people. Find the draft and participate in the consultation here.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE recommends range of effective treatments for people with chronic primary pain and calls on healthcare professionals to recognise and treat a person’s pain as valid and unique to them07/04/2021 13:20:00
People with chronic primary pain should be offered a range of treatments to help them manage their condition, NICE has said in its guideline on the assessment and management of chronic pain published today (7 April)
Starting with the end in mind - the Innovative Licensing and Access Pathway29/03/2021 16:15:00
Blog posted by: Nick Crabb and Meindert Boysen, NICE's members on the ILAP Steering Group, 26 March 2021.
NICE publishes single guideline for managing COVID-1924/03/2021 11:15:00
One year on from the first national lockdown, NICE yesterday (23 March) published a single guideline for the management of COVID-19 in children and adults.
Triple therapy recommended by NICE for patients with multiple myeloma23/03/2021 14:15:00
The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.
Unpaid carers should be offered advice and support, says NICE19/03/2021 15:25:00
NICE has today published a new quality standard aimed at improving the wellbeing of adults who provide unpaid care for people over 16 years old
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund19/03/2021 12:20:00
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia19/03/2021 11:15:00
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE approves life-changing gene therapy for treating spinal muscular atrophy09/03/2021 16:15:00
A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.